GILEAD SCIENCES, INC. vs Novartis AG, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where GILD and NVS diverge most: on debt / equity, GILD reads 1.00 and NVS reads 0.00; on return on invested capital, GILD reads 17.3% and NVS reads 32.4%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | GILD | NVS |
|---|---|---|
| Price | $130.19 | $156.20 |
| Market cap | $163.3B | $302.9B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +2.9% |
| P/E | 17.7 | 21.7 |
| P/B | 6.94 | 6.51 |
| P/S | 5.49 | 5.55 |
| EV/EBITDA | 17.4 | 16.5 |
| Revenue growth | +3.5% | +6.4% |
| Gross margin | — | 78.8% |
| Operating margin | 37.2% | 32.4% |
| Net margin | 31.0% | 25.6% |
| Return on equity | 39.2% | 30.0% |
| Return on assets | 16.4% | 12.6% |
| Return on invested capital | 17.3% | 32.4% |
| FCF yield | 6.3% | 5.8% |
| Dividend yield | 2.4% | — |
| Debt / equity | 1.00 | 0.00 |
| Current ratio | 1.97 | 1.12 |
| Altman Z (solvency) | 7.23 | 3.87 |
| Piotroski F (quality) | 6 / 9 | 8 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.